Based on the Repligen Corporation stock forecast from 8 analysts, the average analyst target price for Repligen Corporation is USD 190.00 over the next 12 months. Repligen Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Repligen Corporation is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Repligen Corporation’s stock price was USD 124.73. Repligen Corporation’s stock price has changed by -11.35% over the past week, -13.97% over the past month and -20.01% over the last year.
No recent analyst target price found for Repligen Corporation
No recent average analyst rating found for Repligen Corporation
Company Overview Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Read Less
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affin...Read More
Frequently Asked Questions About Repligen Corporation (RGEN) Stock
Based on ratings from 8 analysts Repligen Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on RGEN's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for RGEN is USD 190.00 over the next 12 months. The maximum analyst target price is USD 220 while the minimum anlayst target price is USD 155.
RGEN stock's Price/Earning ratio is 458.56.
Our analysis grades RGEN stock's Price / Earning ratio at F. This means that RGEN stock's Price/Earning ratio is above 96% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this RGEN may be a overvalued for its sector.
The last closing price of RGEN's stock was USD 124.73.
The most recent market capitalization for RGEN is USD 7.52B.
Based on targets from 8 analysts, the average taret price for RGEN is projected at USD 190.00 over the next 12 months.
This means that RGEN's stock price may go up by +52.33% over the next 12 months.
We can't find any ETFs which contains Repligen Corporation's stock.
As per our most recent records Repligen Corporation has 1,783 Employees.
Repligen Corporation's registered address is Building 1, Waltham, MA, United States, 02453.
You can get more information about it from Repligen Corporation's website at https://www.repligen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Repligen Corporation (RGEN) Stock
Based on ratings from 8 analysts Repligen Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on RGEN's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for RGEN is USD 190.00 over the next 12 months. The maximum analyst target price is USD 220 while the minimum anlayst target price is USD 155.
RGEN stock's Price/Earning ratio is 458.56.
Our analysis grades RGEN stock's Price / Earning ratio at F. This means that RGEN stock's Price/Earning ratio is above 96% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this RGEN may be a overvalued for its sector.
The last closing price of RGEN's stock was USD 124.73.
The most recent market capitalization for RGEN is USD 7.52B.
Based on targets from 8 analysts, the average taret price for RGEN is projected at USD 190.00 over the next 12 months.
This means that RGEN's stock price may go up by +52.33% over the next 12 months.
We can't find any ETFs which contains Repligen Corporation's stock.
As per our most recent records Repligen Corporation has 1,783 Employees.
Repligen Corporation's registered address is Building 1, Waltham, MA, United States, 02453.
You can get more information about it from Repligen Corporation's website at https://www.repligen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RGEN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
